key: cord-0999315-na00704u
authors: Shirato, Ken; Takanari, Jun; Kizaki, Takako
title: ETAS®50 Attenuates SARS-CoV-2 Spike Protein-Induced IL-6 and IL-1β Production by Suppressing p44/42 MAPK and Akt Phosphorylation in Murine Primary Macrophages
date: 2021-07-26
journal: bioRxiv
DOI: 10.1101/2021.07.25.453717
sha: 75567ca4baa69393a6376595de3a4653f84f29f2
doc_id: 999315
cord_uid: na00704u

Excessive host inflammation following infection with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is associated with severity and mortality in coronavirus disease 2019 (COVID-19). We recently reported that the SARS-CoV-2 spike protein S1 subunit (S1) induces pro-inflammatory responses by activating toll-like receptor 4 (TLR4) signaling in macrophages. ETAS®50, a standardized extract of Asparagus officinalis stem, is a unique functional food that elicits anti-photoaging effects by suppressing pro-inflammatory signaling in hydrogen peroxide- and ultraviolet B-exposed skin fibroblasts. To elucidate its potential in preventing excessive inflammation in COVID-19, we examined the effects of ETAS®50 on pro-inflammatory responses in S1-stimulated murine peritoneal exudate macrophages. Co-treatment of the cells with ETAS®50 significantly attenuated S1-induced secretion of interleukin (IL)-6 in a concentration-dependent manner without reducing cell viability. ETAS®50 also markedly suppressed the S1-induced transcription of IL-6 and IL-1β. However, among the TLR4 signaling proteins, ETAS®50 did not affect the degradation of inhibitor κBα, nuclear translocation of nuclear factor-κB p65 subunit, and phosphorylation of c-Jun N-terminal kinase p54 subunit after S1 exposure. In contrast, ETAS®50 significantly suppressed S1-induced phosphorylation of p44/42 mitogen-activated protein kinase (MAPK) and Akt. Attenuation of S1-induced transcription of IL-6 and IL-1β by the MAPK kinase inhibitor U0126 was greater than that by the Akt inhibitor perifosine, and the effects were potentiated by simultaneous treatment with both inhibitors. These results suggest that ETAS®50 attenuates S1-induced IL-6 and IL-1β production by suppressing p44/42 MAPK and Akt signaling in macrophages. Therefore, ETAS®50 may be beneficial in regulating excessive inflammation in patients with COVID-19.

stem, was prepared from unused parts of asparagus in the factory of Amino Up Co., Ltd.

(Sapporo, Japan) [17, 18, 22] . The asparagus is grown in Hokkaido, Japan and is commonly in the marketplace. In brief, Asparagus officinalis L. stems were collected and dried, and then extracted with hot water at 100 °C for 45 min. The extract was cooled to 50 °C and treated with cellulase and hemicellulase for 18 h to avoid clogging during production. After inactivation (100 °C, 20 min) of the enzymes, the extract was separated by centrifugation, concentrated in vacuo, and mixed with dextrin as a filler. The mixture was sterilized at 121 °C for 45 min and then spray-dried to produce ETAS®50 powder, consisting of 50% solid content of asparagus extract and 50% dextrin. Component analysis showed that the ETAS®50 powder comprised 78.5% carbohydrates, 12.3% proteins, 5.0% ashes, 0.7% lipids, and 3.5% moisture. The manufacturing process was conducted in accordance with good manufacturing practice standards for dietary supplements and ISO9001:2015 and ISO22000:2018 criteria.

Service, Tokyo, Japan) were housed at a temperature of 23-25 °C and humidity of 50%-60% with a fixed light/dark cycle (light, 7:00-19:00; dark, 19:00-7:00). Food and water were provided ad libitum. This study was approved by the Experimental Animal Ethics Committee in Kyorin University (No. 245, 2021) . All experiments described below were carried out following the Guiding Principles for the Care and Use of Animals approved by the Council of the Physiological Society of Japan, in accordance with the Declaration of Helsinki, 1964. Lakes, NJ, USA) was administered intraperitoneally into the mice, and the mice were housed for four days [14, 28] . After the mice were euthanized by cervical dislocation, peritoneal exudate cells were harvested by sterile lavage of the peritoneal cavity with ice-cold Dulbecco's modified Eagle's medium (DMEM; Nacalai Tesque, Kyoto, Japan). The cells were washed once with ice-cold DMEM, resuspended in DMEM supplemented with 10% heat-inactivated fetal bovine serum (BioWest, Nuaillé, France), 100 units/ml penicillin (Nacalai Tesque), and 100 μg/ml streptomycin (Nacalai Tesque), and then cultured at 37 °C in a humidified incubator containing 5% CO2 for 1 h. After the nonadherent cells were removed, peritoneal exudate macrophages were used in the experiments.

(0.25, 0.5, 1, or 2 mg/mL) were prepared by directly dissolving each agent in the complete medium, and then the supplemented medium was filter sterilized using a 0.22 μm membrane [21, [24] [25] [26] [27] . To assess its anti-inflammatory effects, the cells were co-treated with the indicated concentrations of ETAS®50 or dextrin and 100 ng/mL of SARS-CoV-2 spike recombinant protein S1 subunit (Arigo Biolaboratories, Hsinchu City, Taiwan) for 1 to 24 h.

The cells were treated with 20 μM nigericin (Sigma-Aldrich, St. Louis, MO, USA) for the last 1 h of S1 stimulation to promote IL-1β processing and secretion. Cells were co-treated with 5 μM U0126 (Cell Signaling Technology, Danvers, MA, USA) or 20 μM perifosine (Cell Signaling Technology) to block S1-induced phosphorylation of p44/42 MAPK or Akt, respectively. The final concentrations of vehicles used to dissolve these agents were equivalent to the culture medium used among the experimental groups.

Cell culture supernatants were collected after centrifugation at 300 × g for 20 min. Concentrations of IL-6 and IL-1β were measured using the Quantikine Mouse IL-6 ELISA Kit (R&D Systems, Minneapolis, MN, USA) and

Quantikine Mouse IL-1β ELISA Kit (R&D Systems), as described previously [14, 28] . Since the detection limits of IL-6 and IL-1β for ELISA are 7.8-500 pg/mL and 12.5-800 pg/mL, respectively, the supernatants were diluted 10 times before measurements.

2.6. Cell viability assay. Cell viability was measured using the Cell Counting Kit-8 (FUJIFILM Wako Pure Chemical, Osaka, Japan) [29] . After cell culture supernatants were collected, fresh complete medium supplemented with 10% Cell Counting Kit-8 reagent was added to each well, and incubation was continued for 1 h. After the reaction was stopped by adding 1% sodium dodecyl sulfate, the absorbance of medium in each well was analyzed using a multi-mode microplate reader FilterMax F5 (Molecular Devices, San Jose, CA, USA) at a wavelength of 450 nm. Cell viability was calculated with the viability of vehicle-treated control cells as 100%.

RNA was extracted using RNAiso Plus reagent (TaKaRa Bio, Shiga, Japan). One microgram of total cellular RNA was converted to single-stranded cDNA using the PrimeScript 1st Table 1 . The mRNA expression levels of target genes were calculated as the ratio of their values to that of 18S rRNA as an internal control. Assay BCA kit (Nacalai Tesque).

Whole or nuclear proteins (10 μg) were separated through electrophoresis on a sodium dodecyl sulfate-polyacrylamide gel and then transferred onto an Immobilon-P membrane (Merck Millipore, Burlington, MA, USA). After blocking with 5% bovine serum albumin, each membrane was probed with primary antibodies for 1 h (Table 2) .

Laboratories, West Grove, PA, USA) were applied at a 1:20,000 dilution for 30 min. The membrane was incubated with Western BLoT Chemiluminescence HRP Substrate (TaKaRa Bio), and membrane image was captured using a chemiluminescent imaging system LuminoGraph I (ATTO, Tokyo, Japan). The density of each protein band was quantified using ImageJ software (National Institutes of Health, Bethesda, MD, USA). Glyceraldehyde-3-phosphate dehydrogenase (GAPDH) and Yin Yang 1 (YY1) were used as loading controls for whole and nuclear proteins, respectively. The phosphorylation levels of the target proteins were calculated as the ratio of their values to those of the corresponding total protein as a loading control. 2.11. Statistical analysis. Experimental data are presented as mean ± standard error of the mean (SEM). Comparisons among at least three groups were tested using one-way analysis of variance (ANOVA), and post hoc comparisons to determine significant differences between two groups were performed using the Bonferroni test. Differences were considered statistically significant at p < 0.05.

without reducing the cell viability of macrophages. To elucidate whether ETAS®50 has antiinflammatory effects on S1-stimulated macrophages, we first examined the concentrationdependent effects of ETAS®50 treatment on S1-induced secretion of IL-6 in murine peritoneal exudate macrophages. When the cells were simultaneously treated with different concentrations (0, 0.25, 0.5, 1, or 2 mg/mL) of ETAS®50 and 100 ng/mL of S1 for 6 h, ETAS®50 significantly attenuated S1-induced secretion of IL-6 in a concentration-dependent manner (Figure 1(a) ). To rule out that the attenuation of the S1-induced IL-6 section by ETAS®50 is due to a reduction in the number of living cells, we conducted a cell viability assay under the same experimental conditions. The cells stimulated with S1 alone showed significant increase in cell viability, which was not influenced by ETAS®50 treatment (Figure 1(b) ).

To confirm that the ETAS®50 treatment attenuates S1-induced secretion of IL-6 by transcriptional repression, we next analyzed the effects of ETAS®50 treatment on S1-induced transcription of IL-6 and IL-1β in murine peritoneal exudate macrophages. When the cells were simultaneously treated with 2 mg/mL of ETAS®50 and 100 ng/mL of S1 for 6 h, ETAS®50 dramatically repressed S1-induced transcription of IL-6 and IL-1β (Figure 2(a) ).

Moreover, extending the treatment time from 6 h to 24 h potentiated the attenuating effect of ETAS®50 on S1-induced secretion of IL-6 ( Figure 1 (a) and 2(b): left). Moreover, ETAS®50 strongly attenuated nigericin-induced secretion of IL-1β after priming the cells with S1 stimulation for 24 h (Figure 2(b) : right).

affecting NF-κB nuclear translocation and JNK phosphorylation in macrophages. We recently reported that S1-induced transcription of pro-inflammatory cytokines is regulated by NF-κB and JNK signaling [14] . Therefore, we analyzed whether ETAS®50 suppresses S1induced activation of NF-κB and JNK signaling in murine peritoneal exudate macrophages.

Western blotting revealed that co-treatment of the cells with ETAS®50 (2 mg/mL) for 1 h did not affect S1 (100 ng/mL)-induced degradation of inhibitor κBα (IκBα), nuclear accumulation of NF-κB p65 subunit, and phosphorylation of JNK p54 subunit (Figure 3(a) ).

Immunofluorescence data also supported the result that ETAS®50 did not inhibit the S1induced nuclear translocation of p65 (Figure 3(b) ). However, instead of inhibiting the activation of NF-κB and JNK signaling, ETAS®50 significantly suppressed S1-induced phosphorylation of p44/42 MAPK and Akt after 6 h of co-treatment without interfering with basal phosphorylation levels ( Figure 4 ).

1β transcription in macrophages. To clarify whether p44/42 MAPK and Akt signaling mediate S1-induced pro-inflammatory responses, we examined the effects of the MAPK kinase inhibitor U0126 and Akt inhibitor perifosine on S1-induced transcription of IL-6 and IL-1β in murine peritoneal exudate macrophages. Co-treatment of the cells with 5 μM U0126

abolished S1-induced phosphorylation of p44/42 MAPK after 6 h ( Figure 5(a) ). At the same time, S1-induced transcription of IL-6 was significantly decreased by half, and that of IL-1β was dramatically suppressed (Figure 5(b) ). On the other hand, co-treatment of the cells with 20 μM perifosine significantly mitigated S1-induced phosphorylation of Akt after 6 h ( Figure   6 (a)), which was accompanied by significant repression of S1-induced transcription of IL-1β, but not of IL-6 ( Figure 6(b) ). When the cells were simultaneously treated with U0126 and perifosine to mimic the condition treated with ETAS®50, transcriptional repression of IL-6

and IL-1β was augmented compared to treatment with each inhibitor alone (Figure 7 ).

The pro-inflammatory cytokine IL-6 has been suggested to be involved in the aggravation of patients with COVID-19 [15, 16] . In the initial experiment, we found that cotreatment with ETAS®50 attenuated S1-induced secretion of IL-6 in murine peritoneal exudate macrophages in a concentration-dependent manner after 6 h of culture. In addition, this result is not due to a reduction in the number of living cells, since ETAS®50 did not influence cell viability. The viability of S1-treated cells was significantly higher than that in vehicle-treated control cells. However, primary cultured macrophages were terminally differentiated and therefore cannot undergo cell proliferation. . Therefore, our results suggest that S1 activates the enzymes in macrophages as TLR4 agonist in a manner similar to the action of LPS, and that ETAS®50

can attenuate S1-induced production of IL-6 without impairing cell survival and metabolism.

The attenuation of S1-induced IL-6 secretion is due to its transcriptional repression, since ETAS®50 co-treatment dramatically repressed S1-induced transcription of IL-6 after 6 h of culture. Moreover, when the treatment time was extended from 6 h to 24 h, the attenuating effect of ETAS®50 on S1-induced IL-6 secretion was clearly potentiated. These results suggest that ETAS®50 has a weak or no suppressive effect on S1-induced signal transduction in the early phase, such as NF-κB and JNK signaling, which regulates the transcription of IL-6. We recently reported that S1 induces IκBα degradation, NF-κB p65 subunit nuclear translocation, and JNK phosphorylation by interacting with TLR4 in macrophages within 1 h of culture [14] . Indeed, in this study, co-treatment with ETAS®50

did not suppress the activation of NF-κB and JNK signaling by S1 exposure. In contrast, ETAS®50 treatment suppressed NF-κB p65 nuclear translocation and JNK phosphorylation in hydrogen peroxide-or ultraviolet B-exposed skin fibroblasts [24] [25] [26] . The discrepancy in the action mechanisms of ETAS®50 may be due to the difference in upstream signal transduction pathways between TLR4 and other stress-triggered signaling pathways.

It has been also suggested that suppressing the action of IL-1 may be a therapeutic target for critically-ill patients with COVID- 19 [15] . In this study, ETAS®50 co-treatment dramatically repressed S1-induced transcription of IL-1β. The regulatory machinery for IL-1β

processing and secretion substantially differs from that of most other pro-inflammatory cytokines, including IL-6. IL-1β is initially synthesized as a leaderless precursor that requires cleavage into its active form by inflammasome-activated caspase- Therefore, ETAS®50 attenuated both S1-induced IL-6 and IL-1β production by repressing their transcription in macrophages.

In addition to NF-κB and JNK signaling, the activation of p44/42 MAPK and Akt signaling was observed to regulate the transcription of pro-inflammatory cytokines in macrophages. Indeed, it has been reported that a wide variety of herbal extracts and herbderived natural compounds exert anti-inflammatory effects on LPS-stimulated macrophage cell lines, such as RAW264.7 and U937, by suppressing either p44/42 MAPK signaling [37] [38] [39] [40] or Akt signaling [41] [42] [43] . In this regard, we found that ETAS®50 co-treatment suppressed S1-induced phosphorylation of p44/42 MAPK and Akt after 6 h of culture.

Moreover, S1-induced transcription of IL-6 and IL-1β was largely regulated by p44/42 MAPK signaling in murine peritoneal exudate macrophages, since the transcriptional induction was significantly repressed by co-treatment with the MAPK kinase inhibitor U0126. In contrast, Akt signaling had a minor contribution to the transcriptional induction of IL-6 and IL-1β by S1 exposure compared to p44/42 MAPK signaling, as the Akt inhibitor perifosine partially repressed IL-1β transcription but did not influence IL-6 transcription.

Simultaneous suppression of S1-induced phosphorylation of p44/42 MAPK and Akt augmented the repression of S1-induced IL-6 and IL-1β transcription, suggesting that ETAS®50 dramatically attenuated S1-induced IL-6 and IL-1β production by simultaneously suppressing both p44/42 MAPK and Akt signaling. However, the unknown actions of ETAS®50 should be considered, because IL-6 transcription could not be dramatically related mortality in the critical care setting: a national cohort study in England, March-July 2020," Diabetes Care, vol. 44, no. 1, pp. 50-57, 2021.

[10] N. Holman, P. Knighton, P. Kar et al., "Risk factors for COVID-19-related mortality in people with type 1 and type 2 diabetes in England: a population-based cohort study,"

The Lancet. Diabetes & Endocrinology, vol. 8, no. 10, pp. 823-833, 2020. 

The epidemiological characteristics of an outbreak of 2019 novel coronavirus diseases (COVID-19)-China, 2020

Characteristics of and important lessons from the coronavirus disease 2019 (COVID-19) outbreak in China: summary of a report of 72 314 cases from the Chinese Center for Disease Control and Prevention

Is older age associated with COVID-19 mortality in the absence of other risk factors? General population cohort study of 470,034 participants

Age-specific mortality and immunity patterns of SARS-CoV-2

Body mass index and risk for intubation or death in SARS-CoV-2 infection: a retrospective cohort study

Body mass index and risk for COVID-19-related hospitalization, intensive care unit admission, invasive mechanical ventilation, and death-United States

Obesity and mortality among patients diagnosed with COVID-19: results from an integrated health care organization

Associations of type 1 and type 2 diabetes with COVID-19-related mortality in England: a whole-population study

Type 2 diabetes and COVID-19-hyper-inflammation

Interleukin-6 receptor antagonists in critically ill patients with covid-19

Effects of enzyme-treated asparagus extract on heat shock protein 70, stress indices, and sleep in healthy adult men

Enzyme-treated asparagus extract promotes expression of heat shock protein and exerts antistress effects

Effect of enzyme-treated asparagus extract (ETAS) on psychological stress in healthy individuals

Neuroprotective effects of Asparagus officinalis stem extract in transgenic mice overexpressing amyloid precursor protein

A standardized extract of Asparagus officinalis stem prevents reduction in heat shock protein 70 expression in ultraviolet-B-irradiated normal human dermal fibroblasts: an in vitro study

Isolation, structural elucidation, and biological evaluation of a 5-hydroxymethyl-2-furfural derivative, asfural, from enzyme-treated asparagus extract

Isolation and structure determination of a heat shock protein inducer, asparagus-derived prolinecontaining 3-alkyldiketopiperazines (Asparaprolines), from a standardized extract of Asparagus officinalis stem

Enzyme-treated asparagus extract attenuates hydrogen peroxide-induced matrix metalloproteinase-9 expression in murine skin fibroblast L929 cells

Enzyme-treated asparagus extract prevents hydrogen peroxide-induced pro-inflammatory responses by suppressing p65 nuclear translocation in skin L929 fibroblasts

Anti-inflammatory effect of ETAS ® 50 by Radix regulates inflammatory response in LPS-stimulated RAW264.7 macrophages through MAPKs and NF-κB Pathway

Oleifolioside A, a new active compound, attenuates LPS-stimulated iNOS and COX-2 expression through the downregulation of NF-κB and MAPK activities in RAW 264.7 macrophages

Literature-based drug repurposing in traditional Chinese medicine: reduced inflammatory M1 macrophage polarization by Jisil Haebaek Gyeji-Tang alleviates cardiovascular disease in vitro and ex vivo

Anti-inflammatory and antioxidant effects of Chaetoglobosin Vb in LPS-induced RAW264.7 cells: achieved via the MAPK and NF-κB signaling pathways

The anti-inflammatory effects of lignan glycosides from Cistanche tubulosa stems on LPS/IFN-γ-induced RAW264.7 macrophage cells via PI3K/AKT pathway

Standardized ethanol extract of Tinospora crispa upregulates pro-inflammatory mediators release in LPS-primed U937 human macrophages through stimulation of MAPK, NF-κB and PI3K-Akt signaling networks

Cornus officinalis var. koreana Kitam polyphenol extract decreases pro-inflammatory markers in lipopolysaccharide (LPS)-induced RAW 264.7 macrophages by reducing Akt phosphorylation

ERK signalling as a regulator of cell motility

Proliferation, survival and metabolism: the role of PI3K/AKT/mTOR signalling in pluripotency and cell fate determination

Toxicological assessment of enzyme-treated asparagus extract in rat acute and subchronic oral toxicity studies and genotoxicity tests

This study was supported by a Grant-in-Aid for Scientific Research (C) (21K11472: K.